The European Commission is now awaiting marketing authorization from the European Medicines Agency.
While a new version of Moderna’s vaccine, supposed to fight the Omicron variant more effectively, is expected, the European Union has reserved 15 million of these doses. Doses which are part of the 460 million in the global order placed with Moderna, by the European Commission, at the start of the pandemic.
This new agreement nevertheless remains “subject to marketing authorization (in the EU) within a time frame that would allow the use of these doses for vaccination campaigns”, explains a press release. The European Medicines Agency (EMA) announced that it was looking into this new vaccine last June.
The European Commission has also announced that it has reached an agreement with the American company regarding the delivery schedule in order to “to better respond to the needs of the Member States”.
